Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IQP-0528是一种高效的非核苷类逆转录酶抑制剂(NNRTI),通过阻断病毒进入,有可能用于治疗HIV 感染,并且作为杀微生物凝胶显示出抗病毒活性。IQP-0528对HIV-1和HIV-2都显示出抑制作用,对HIV-1的EC50为0.2 nM,对HIV-2的EC50为100 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 930 | 现货 | ||
5 mg | ¥ 2,260 | 现货 | ||
10 mg | ¥ 3,380 | 现货 | ||
25 mg | ¥ 5,490 | 现货 | ||
50 mg | ¥ 7,720 | 现货 | ||
100 mg | ¥ 9,870 | 现货 | ||
500 mg | ¥ 19,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,160 | 现货 |
产品描述 | IQP-0528 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) that has potential for the treatment of HIV infection by blocking viral entry and shows antiviral activity as a microbicidal gel. . IQP-0528 showed inhibition of both HIV-1 and HIV-2, with an EC50 of 0.2 nM for HIV-1 and 100 nM for HIV-2. |
靶点活性 | HIV-1:0.2 nM(EC50), HIV-2:100 nM(EC50) |
体外活性 | The in vitro safety evaluations showed no significant loss in cell viability or significant inflammatory response after treatment with a 3.0% HEC gel containing 0.25% IQP-0528. In an in vitro HIV-1 entry inhibition assay, the lead formulation showed an 50% effective concentration of 0.14 μg/ml for gel in culture media, which corresponds to ∼0.001 μM IQP-0528.[5] |
体内活性 | we report the first-in-human evaluation of such a gel containing 1% IQP-0528, an investigational antiretroviral. Seven HIV-1-negative participants received one 10 mL rectal dose of radiolabeled 1% IQP-0528 gel. Median IQP-0528 concentrations in rectal tissue exceeded the in vitro EC95 against HIV-1 (0.07 ng/mg) by 3-5 h of dosing and remained above this concentration for at least 24 h, despite a 3-log reduction in concentration over this duration of time. Rectal tissue PD assessed by ex vivo HIV challenge-demonstrated significant p24 antigen reduction 3-5 h postdose compared with baseline , but not 24-26 h postdose. The IQP-0528 gel possesses desirable features for a topical microbicide including local safety with no systemic absorption, delivery of locally high IQP-0528 concentrations, and significant reductions in ex vivo HIV infectivity.[6] |
别名 | SJ-3991, SJ3991, IQP0528 |
分子量 | 340.42 |
分子式 | C20H24N2O3 |
CAS No. | 301297-45-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4 mg/mL (11.75 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9375 mL | 14.6877 mL | 29.3755 mL | 73.4387 mL |
5 mM | 0.5875 mL | 2.9375 mL | 5.8751 mL | 14.6877 mL | |
10 mM | 0.2938 mL | 1.4688 mL | 2.9375 mL | 7.3439 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
IQP-0528 301297-45-0 Immunology/Inflammation Microbiology/Virology Proteases/Proteasome Antiviral HIV Protease Reverse Transcriptase SJ 3991 IQP 0528 SJ-3991 SJ3991 IQP0528 Inhibitor inhibitor inhibit